Know Cancer

forgot password

Exercise for Physical Health in Men With Prostate Cancer

18 Years
Not Enrolling
Prostatic Neoplasm, Osteoporosis

Thank you

Trial Information

Exercise for Physical Health in Men With Prostate Cancer

Prostate cancer survivors with advanced disease are commonly treated with androgen
deprivation therapy (ADT) to reduce testosterone. Serious side effects of ADT are rapid bone
and muscle loss that can lead to osteoporosis and declines in neuromuscular function
(strength, power, gait and balance) which increases the risk of fracture and falls (a risk
factor for fracture) and impairs physical function. Men on ADT are 1.4 times more likely to
fracture compared with their cancer-free peers and those who fracture have a poorer
prognosis than those who do not. Self-report physical function is also lower among men on
ADT. Exercise can prevent bone loss, neuromuscular declines and falls in several
populations. However, the ability of exercise to prevent bone loss from ADT has not been
tested, while data on exercise and neuromuscular function (strength only) in this population
are limited to one published trial. The long-term goal of our research is to improve
musculoskeletal health and function in cancer survivors. Critical first steps to meet this
goal are to determine whether our previously tested program of impact and resistance
exercise, shown to improve bone health and neuromuscular function in women, can prevent bone
loss and neuromuscular declines in prostate cancer survivors on ADT. Based on our previous
research, we have developed the POWIR program (Prevent Osteoporosis With Impact +
Resistance) to be adapted to clinical populations at risk for bone loss and declines in
neuromuscular function. Potentially, POWIR could mitigate bone and muscle losses from ADT,
and thereby lower fracture risk and improve quality of life.

Inclusion Criteria:

- histologically confirmed prostate cancer

- presently receiving or planning to begin androgen deprivation therapy for prostate

Exclusion Criteria:

- Presence of bone metastases in the proximal femur and lumbar spine

- Clinically defined osteoporosis

- Current or previous use of medications known to affect bone metabolism

- Current regular participation (>2x/wk for at least 30 min/session) in a planned
session of moderate-vigorous impact or resistance training

- A medical condition, disorder, or medication that contraindicates participation in
moderate intensity impact or resistance exercise

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care

Outcome Measure:

bone mineral density, bone turnover markers (serum osteocalcin, urinary deoxypyridinoline cross-links), muscle mass, fat mass.

Outcome Time Frame:

12 months

Safety Issue:


Principal Investigator

Kerri M Winters, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Oregon Health and Science University


United States: Institutional Review Board

Study ID:




Start Date:

January 2006

Completion Date:

January 2009

Related Keywords:

  • Prostatic Neoplasm
  • Osteoporosis
  • randomized clinical trial
  • elderly
  • cancer survivor
  • bone health
  • body composition
  • signs and symptoms
  • Androgen Deprivation Therapy
  • Neoplasms
  • Osteoporosis
  • Prostatic Neoplasms



OHSU School of Nursing Portland, Oregon  97239